Therapeutic solutions for neurodegeneration
There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.
Alzprotect designs and develops innovative therapeutic solutions for these diseases.
Objective: to halt neurodegeneration and restore certain brain functions
An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.
Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.
News
Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial announces the selection of AADvac1 and AZP2006 for its first two regimens
London, United Kingdom – April 25, 2025 –
The Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and Anne-Marie Wills (Massachusetts General Hospital), has selected two promising drug candidates—Axon Neuroscience’s AADvac1 and Alzprotect’s AZP2006—for inclusion in the platform trial as the first two compounds to be evaluated. The trial aims to a...
Alzprotect Announces the Appointment of Professor Christian Bailly to its Board of Directors
Lille, France – December 5th, 2024 – Alzprotect, a pioneering biopharmaceutical company developing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Professor Christian Bailly to its Board of Directors.
Professor Christian Bailly brings to Alzprotect substantial expertise in pharmaceutical research and life sciences, built over more than 30 years of experience. Currently an Associate Professor at the University of Lille and an independent consulta...